In 2023, G42 and Mubadala announced the coming together of G42 Healthcare and Mubadala Health to create a first-of-its-kind, global tech-enabled health powerhouse – M42.

With the vision of impactfully disrupting the global health landscape, M42 combines advanced technologies, such as genomics and AI, with state-of-the-art healthcare facilities, including Cleveland Clinic Abu Dhabi and Imperial College London Diabetes Centre, to deliver the highest level of personalized, precise and preventive health solutions.

In 2023, M42 acquired the world’s second-largest kidney care service provider, Diaverum. The acquisition expanded M42’s global geographic footprint, enabling the company to introduce selected healthcare services and advanced technology solutions in new markets.

Today, M42 has over 20,000 employees across 450 facilities in 26 countries. As a global tech-enabled health company, M42 continues to operate at the forefront of medical advancement, transforming the way care is delivered by bridging the gap between the latest technology advancements and the clinical outcomes patients receive.

The formation of M42 is a significant and positive development for the future of global health and a major milestone for Abu Dhabi, which continues to advance its status as a leader in the global life sciences.